Belinostat for the treatment of T-cell lymphoma

Bibliography

• Marchi E, Mangone M, Zullo K, O’Connor OA. Pralatrexate pharmacology and clinical development. Clin Cancer Res 2013;19(24):6657-61
   PubMed Web of Science ®Google Scholar
• Marchi E, O’Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol 2012;3(4):227-35
   Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9
   PubMed Web of Science ®Google Scholar
• Zain J, O’Connor O. Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother 2010;11(10):1705-14
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24(1):166-73
   PubMed Web of Science ®Google Scholar
• Zain JM, O’Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int J Hematol 2010;92(1):33-44
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019-32
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-30
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105(10):3768-85
   PubMed Web of Science ®Google Scholar
• Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 2009;1789(1):45-57
   PubMed Web of Science ®Google Scholar
• Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107(4):600-8
   PubMed Web of Science ®Google Scholar
• Rada-Iglesias A, Enroth S, Ameur A, et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 2007;17(6):708-19
   PubMed Web of Science ®Google Scholar
• Spange S, Wagner T, Heinzel T, Krämer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41(1):185-98
   PubMed Web of Science ®Google Scholar
• Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010;1(5):55-61
   Google Scholar
• Zain J, O’Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 2010;28(Suppl 1):S58-78
   PubMed Web of Science ®Google Scholar
• Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010;19(9):1049-66
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97(18):10014-19
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan J, Zhuang L, et al. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005;102(44):16090-5
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
   PubMed Web of Science ®Google Scholar
• Zhang Y, Carr T, Dimtchev A, et al. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 2007;168(1):115-24
   PubMed Web of Science ®Google Scholar
• Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011;2011:830260
   Google Scholar
• Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8(6):464-78
   PubMed Web of Science ®Google Scholar
• Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2(8):721-8
   PubMed Web of Science ®Google Scholar
• Marchi E, Kalac M, Bongero D, et al. Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. ASH Annual Meeting Abstracts 2011;118(21):2727
   Google Scholar
• Wang L, Goh BC, Lwin TW, et al. Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma. ASCO Annual Meeting Abstracts 2010;28(15):2585
   Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14(3):804-10
   PubMed Web of Science ®Google Scholar
• Wang LZ, Ramírez J, Yeo W, et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One 2013;8(1):e54522
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 2011;67(6):1273-9
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29(9):1198-203
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6
   PubMed Web of Science ®Google Scholar
• Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008;81(3):170-6
   PubMed Web of Science ®Google Scholar
• Zain JM, Foss FM, Diefenbach CS, et al. Preliminary results of an ongoing phase I trial of oral belinostat a novel histone deacetylase inhibitor in patients with lymphoid malignancies. ASH Annual Meeting Abstracts 2011;118(21):3710
   Google Scholar
• Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in Patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. ASH Annual Meeting Abstracts 2009;114(22):920
   Google Scholar
• O’Connor OA, Masszi T, Savage K, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. ASCO Annual Meeting Abstracts 2013;31(15):8507
   Google Scholar
• BELEODAQ™ (belinostat) for injection [prescribing information]. Spectrum Pharmaceuticals, Inc; Henderson, NV: 2014
   Google Scholar
• Paoluzzi L, Scotto L, Marchi E, et al. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res 2010;16(2):554-65
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-34
   PubMed Web of Science ®Google Scholar